Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 18 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Tenaya Therapeutics, Inc.

Oncology Institute, Inc.

Deeply undervalued

Discount 43% Return to IV: +74.6%

Market implies -7.6%/yr vs model +25.5% · below model

Oncology Institute, Inc.

Market implies -50.0%/yr vs model +25.5% · below model

Theriva Biologics, Inc.

Tempest Therapeutics, Inc.

Traws Pharma, Inc.

Deeply undervalued

Discount 51% Return to IV: +104.7%

Market implies -13.3%/yr vs model +50.0% · below model

First Tracks Biotherapeutics, Inc.

Entrada Therapeutics, Inc.

Market implies +34.2%/yr vs model +15.0% · above model

TRINITY BIOTECH PLC

Deeply overvalued

Premium +377% Return to IV: -79.0%

Owner yield 3.4% 10-yr IRR 1.8% · steady

Market implies +25.5%/yr vs model +4.3% · above model

Deeply overvalued

Premium +224% Return to IV: -69.2%

Owner yield 2.7% 10-yr IRR 4.6% · moderate

Market implies +24.7%/yr vs model +12.0% · above model

Trevi Therapeutics, Inc.

Taysha Gene Therapies, Inc.

Market implies +83.9%/yr vs model +15.0% · above model

Trane Technologies plc

Deeply overvalued

Model IV$312.57

Premium +37% Return to IV: -27.2%

Owner yield 2.7% 10-yr IRR 4.5% · grower

Market implies +14.0%/yr vs model +12.4% · in line

Turn Therapeutics Inc.

Tvardi Therapeutics, Inc.

Market implies -1.3%/yr vs model +15.0% · below model

Travere Therapeutics, Inc.

Deeply overvalued

Premium +199% Return to IV: -66.6%

Market implies +18.7%/yr vs model +38.9% · below model

Twist Bioscience Corp

Market implies +49.9%/yr vs model +29.9% · above model

10x Genomics, Inc.

Market implies +41.7%/yr vs model +7.0% · above model

TherapeuticsMD, Inc.

Deeply undervalued

Discount 49% Return to IV: +96.5%

Market implies -7.0%/yr vs model +5.9% · below model

Tyra Biosciences, Inc.

UFP TECHNOLOGIES INC

Deeply undervalued

Model IV$446.42

Discount 38% Return to IV: +60.6%

Owner yield 2.8% 10-yr IRR 6.9% · grower

Market implies +11.1%/yr vs model +24.5% · below model

UNIVERSAL HEALTH SERVICES INC

Deeply undervalued

Model IV$468.11

Discount 62% Return to IV: +164.9%

Owner yield 7.3% 10-yr IRR 19.1% · grower

Market implies -2.2%/yr vs model +12.8% · below model

Unicycive Therapeutics, Inc.

Market implies +62.3%/yr vs model +15.0% · above model

Upstream Bio, Inc.

Market implies +66.4%/yr vs model +9.5% · above model

Universe Pharmaceuticals INC

Market implies -50.0%/yr vs model +50.0% · below model

UroGen Pharma Ltd.

Market implies +37.7%/yr vs model +23.0% · above model

USANA HEALTH SCIENCES INC

Deeply undervalued

Discount 71% Return to IV: +240.9%

Market implies -21.5%/yr vs model +2.0% · below model

U S PHYSICAL THERAPY INC /NV

Discount 3% Return to IV: +3.3%

Owner yield 5.6% 10-yr IRR 13.8% · moderate

Market implies +7.6%/yr vs model +11.5% · below model

UNITED THERAPEUTICS Corp

Deeply undervalued

Model IV$1,006.54

Discount 51% Return to IV: +102.5%

Owner yield 4.0% 10-yr IRR 11.8% · grower

Market implies +3.3%/yr vs model +15.1% · below model

UTAH MEDICAL PRODUCTS INC

Discount 19% Return to IV: +23.8%

Owner yield 7.5% 10-yr IRR 13.0% · steady

Market implies -0.4%/yr vs model +5.0% · below model

Vivani Medical, Inc.

Valion Bio, Inc.

Market implies +19.3%/yr vs model +15.0% · above model

Deeply overvalued

Premium +290% Return to IV: -74.3%

Market implies +17.2%/yr vs model +15.9% · in line

Deeply overvalued

Premium +52% Return to IV: -34.3%

Owner yield 2.3% 10-yr IRR 4.4% · grower

Market implies +21.2%/yr vs model +19.7% · in line

Vera Therapeutics, Inc.

Market implies +10.6%/yr vs model +15.0% · below model

Vir Biotechnology, Inc.

Market implies +82.0%/yr vs model +2.0% · above model

VivoSim Labs, INC.

Market implies -7.8%/yr vs model +15.0% · below model

Viking Therapeutics, Inc.

Premium +0% Return to IV: -0.4%

Owner yield 3.9% 10-yr IRR 4.5% · steady

Market implies +5.2%/yr vs model +5.8% · in line

VIEMED HEALTHCARE, INC.

Deeply undervalued

Discount 70% Return to IV: +229.1%

Market implies -23.7%/yr vs model +23.3% · below model

Vanda Pharmaceuticals Inc.

Deeply overvalued

Premium +139% Return to IV: -58.2%

Market implies +9.5%/yr vs model +2.0% · above model

Market implies -0.8%/yr vs model +50.0% · below model

Deeply undervalued

Discount 32% Return to IV: +47.1%

Owner yield 8.3% 10-yr IRR 16.4% · moderate

Market implies +0.5%/yr vs model +7.0% · below model

Vor Biopharma Inc.

Virax Biolabs Group Ltd

Market implies +101.4%/yr vs model +2.0% · above model

Verrica Pharmaceuticals Inc.

Deeply overvalued

Premium +42% Return to IV: -29.4%

Market implies +8.7%/yr vs model +31.2% · below model

Viridian Therapeutics, Inc.DE

Deeply overvalued

Premium +386% Return to IV: -79.4%

Market implies +20.6%/yr vs model +50.0% · below model

VERTEX PHARMACEUTICALS INC / MA

Deeply overvalued

Model IV$284.74

Premium +79% Return to IV: -44.0%

Owner yield 1.5% 10-yr IRR -3.0% · moderate

Market implies +16.6%/yr vs model +11.5% · above model

VSEE HEALTH, INC.

Market implies -50.0%/yr vs model +15.0% · below model

Deeply overvalued

Premium +204% Return to IV: -67.1%

Market implies +15.7%/yr vs model +50.0% · below model

Catheter Precision, Inc.

Deeply undervalued

Discount 96% Return to IV: +2,574.3%

Market implies -50.0%/yr vs model +50.0% · below model

Vistagen Therapeutics, Inc.

Market implies +40.3%/yr vs model +2.0% · above model

Discount 26% Return to IV: +34.6%

Owner yield 10.9% 10-yr IRR 17.4% · steady

Market implies -1.5%/yr vs model +2.9% · below model

vTv Therapeutics Inc.

Vivos Therapeutics, Inc.

Deeply undervalued

Discount 82% Return to IV: +466.6%

Market implies -40.6%/yr vs model +2.0% · below model

Voyager Therapeutics, Inc.

Market implies +67.5%/yr vs model +2.0% · above model